The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research

London

Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest…

Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.

Roots Analysis has announced the addition of “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report to its list of offerings.

The report features an extensive study on the current market landscape…

As per our research, digital therapeutic solutions for metabolic disorders are likely to capture major share (XX%) of the overall market in 2020. This can be attributed to the fact that majority of the solutions are being developed for people with diabetes. This is followed by the solutions developed for mental health problems and substance use disorders. However, given the fact that a significant number of the solutions are being developed for patients with neurological disorders, solutions…

Stringent regulatory guidelines pertaining to cell and gene therapies has made it mandatory for developer companies to conduct extensive preclinical and clinical research to generate the necessary body of evidence, validating the safety, efficacy and benefits of their proprietary products. As a consequence, capital investments required in R&D have increased substantially. It is worth highlighting that even the well-established players in the industry are gradually opting to outsource…

In the pharmaceutical industry, stakeholders are known to adopt a variety partnership models. Such initiatives not only allow the companies to expand their respective product / therapy, but

also to gain additional capabilities in emerging technologies. In the domain of TIL-based therapies, eleven different types of partnership deals were found to be inked between different stakeholders. These include, acquisition, clinical trial agreement, joint venture, manufacturing agreement,…